ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
Science & Medicine
Read more Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Financial & Business Leadership & Corporate
Read more ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
Science & Medicine
Read more STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news


